8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jan 28, 2016)

Filed January 28, 2016For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on January 28, 2016, to report its financial results for the fourth quarter and full year of 2015. The filing primarily directs investors to a press release (Exhibit 99.1) and supplemental information on the company's website (Exhibit 99.2) for detailed financial performance. Investors should refer to these furnished documents for specifics on revenue, earnings, and other key financial metrics for the period ending December 31, 2015. While the 8-K itself does not contain the detailed financial figures, its purpose is to formally announce and provide access to the company's official earnings release. Therefore, the core information for investors lies within the referenced press release and supplemental materials, which would outline the company's operational and financial condition as of the end of 2015 and provide forward-looking statements or guidance that are critical for investment decisions.

Key Highlights

  • 1BMY filed an 8-K on January 28, 2016, reporting Q4 and full-year 2015 financial results.
  • 2The filing incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results.
  • 3Supplemental financial information is also provided via Exhibit 99.2 on the company's website.
  • 4Investors need to consult the furnished press release and supplemental information for specific financial performance data.
  • 5The event date for the reported financial results was January 27, 2016.

Frequently Asked Questions

The detailed financial results for the fourth quarter and twelve months of 2015 are available in the press release furnished as Exhibit 99.1 to this 8-K filing. Additional supplemental information can be found on the company's website (www.bms.com) as Exhibit 99.2.

No, the 8-K filing itself does not contain the detailed financial numbers. It serves as a notification that the company has released its financial results and directs investors to the attached press release (Exhibit 99.1) and supplemental website information (Exhibit 99.2) for those specifics.

This filing is significant because it formally announces Bristol-Myers Squibb's official financial performance for the period ending December 31, 2015. Investors should review the accompanying press release and supplemental materials to understand the company's revenue, profitability, and any outlook or guidance provided.